Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
Metalloproteinase which specifically cleaves IGFBP-5. Additionally we are shipping Pappalysin 2 Antibodies (45) and Pappalysin 2 Proteins (6) and many more products for this protein.
Showing 10 out of 26 products:
Papp-a2 modulates Bmp and Notch (show NOTCH1 ELISA Kits) signaling by independent mechanisms in zebrafish embryos to control cranial cartilage development and angiogenesis.
Locally-produced Pappa2 in osteoblasts, epiphysis, and metaphysis, is required for normal postnatal bone growth.
Despite a dramatic disruption of the balance between circulating IGF-I (show IGF1 ELISA Kits), IGFBP-3 (show IGFBP3 ELISA Kits) and -5, we found no effects of Pappa2 deletion on glucose metabolism, weight gain or adiposity on a high-fat diet.
Pappa2 deletion had no effect on female reproduction and subtle effects on male fertility.
Pappa2 is responsible for the effects of the previously-identified QTL, demonstrating that natural variation in the Pappa2 gene contributes to variation in postnatal growth in mice
investigation of biological role of PAPP-A2 using knockout mice, heterozygotes, primary fibroblasts: The most striking phenotype of PAPP-A2 KO mice was postnatal growth retardation. PAPP-A2 KO mice were fertile, but exhibited compromised fecundity.
Elevated PAPPA2 levels are a consequence rather than a cause of pregnancy complications.
The refinement of the target region to four genes and the finding that the QTL affects IGFBP-5 (show IGFBP5 ELISA Kits) levels suggest that PAPPA2 may be involved with normal postnatal growth
Pappa2 expression also shows specific localization within the mouse embryo and therefore may play roles in fetal development, independent of its action in the placenta
PAPP-A2 is differentially expressed in different trophoblast populations and shows strong down regulation in the mid second trimester in chorionic villous samples.
The association between this PAPPA2 single nucleotide polymorphism and developmental dysplasia of the hip was evaluated.
The upregulation of PAPP-A2 observed in preeclampsia at term occurs early in pregnancy, before the symptoms develop.
PAPPA2 may be upregulated in severe pre-eclampsia and, functionally, this may be mediated via increased placental hypoxia known to occur with this pregnancy disorder.
The existence of this assay will enable an assessment of the biomarker potential of PAPP-A2 in pre-eclampsia as well as other clinical conditions.
Association of a single nucleotide polymorphism in pregnancy-associated plasma protein-A2 with developmental dysplasia of the hip
factors previously known to be highly expressed in preeclamptic placentae (PGE2 and TNF-alpha (show TNF ELISA Kits)), contribute to the upregulation of PAPPA2. results are consistent with the hypothesis that PAPPA2 is upregulated as a consequence of placental pathology
Circulating IGFBP-5 (show IGFBP5 ELISA Kits) is proteolyzed by PAPP-A2 during pregnancy, resulting in increased IGF bioavailability, which may have important consequences for the development of the fetus and/or the well-being of the mother.
PAPP-A2 in syncytiotrophoblast cells was dramatically increased in pre-eclampsia. Maternal serum concentrations of PAPP-A2 were also significantly elevated in pre-eclampsia as compared with uncomplicated pregnancy.
Preeclampsia involves changes in the gene expression of PAPPA2 in placental cytotrophoblasts.
Variants in the pregnancy-associated plasma protein-A2 gene on Bos taurus autosome 16 are associated with daughter calving ease and productive life in Holstein cattle.
Metalloproteinase which specifically cleaves IGFBP-5. Shows limited proteolysis toward IGFBP-3.
, placenta-specific 3
, pregnancy-associated plasma preproprotein-A2
, pregnancy-associated plasma protein-E
, pregnancy-associated plasma protein E1